Technologies
Novel platform technologies for producing immune cytokines that target cancer cells or the tumor microenvironment, designed to induce tumor-specific immunity and eliminate tumors.
MISSION
CytoCan is devoted to developing life-changing Tumor-specific Immune Cytokines (TsICs) to help patients fight cancer. We envision a near future where tumors can be completely eliminated by TsICs, and patients can be protected by immunity specific to cancer.
PLATFORM
We have developed a novel modular platform technology for producing immune cytokines that target cancer cells or the tumor microenvironment (TME). By precisely delivering immune cytokines to specific components of the TME, such as PD-1+ T cells, we aim to stimulate these T cells with TsICs to eliminate cancer cells while minimizing the risk of unintended systemic side effects.
INNOVATION
- Probiokine: A proprietary platform anchored by a humanized IgG-binding domain. Functional antibody-like proteins can be expressed in bacteria or probiotic strains.
- PD-1-Targeting Cytokines: Our technology integrates an optimized PD-1 antibody, precisely binding PD-1 epitopes and carrying potency-optmised cytokines.
PRECISION
We identify unmet medical needs and address difficult-to-treat cancers by designing targeted immune cytokines to eliminate cancer cells. By delivering these treatments specifically to tumor microenvironments, this new class of therapies maximizes tumor-killing efficacy while minimizing systemic and unintended side effects.
about
Find Out More About Us
CytoCan is a biopharmaceutical company specializing in Tumor-specific immune cytokines. In preclinical studies, our PD-1-targeted pipeline candidates have demonstrated complete responses in animal tumor models.
Building a modular platform for Tumor-specific Immune Cytokines
CytoCan is an innovative biopharmaceutical company focused on the research and development of tumor-specific immune cytokines (TsIC). Its core pipeline product is a recombinant TsIC targeting PD-1, positioned as an next generation of PD-1 inhibitor, specifically designed for cancer patients with PD-1 resistance. By targeting PD-1, this product not only blocks the PD-1/PD-L1 interaction but also delivers immunocytokines with optimized activity to the tumor microenvironment (TME) to enable the selective activation of effector T cells. By integrating these three mechanisms of action, this TsIC has achieved complete remission of drug-resistant tumors in mouse models and is expected to overcome the clinical limitations of current PD-1 inhibitors in the future. The company is currently advancing Investigational New Drug (IND) application preparations, with plans to submit dual IND applications in China and the United States within 18 months.
In the News
Press Release - CytoCan received seed round investment
Pipeline
Check our Pipeline
Our Pipeline includes the next generation PD-1/cytokines, and HER2, EGFR and TROP targeted therapies.
| Pipeline | Early Discovery | Preclinical | IND Enabling | Phase I Clinical Trial | Indications |
|---|---|---|---|---|---|
| CC-2401 PD-1 TsIC |
|
PD-1 inhibitor- resistant solid tumors | |||
| CC-2402 PD-1 TsIC |
|
PD-1 inhibitor- resistant solid tumors | |||
| CC-001 HER2 TsIC | breast cancer, gastric cancer | ||||
Contact
Contact Us
Feel free to contact us by mail, email or phone with your inquiry.
Our Hangzhou Office:
Nuohua Industry Park Building A, Floor 18-19,
309 Gaoxin 11 Road
Xiaoshan District
Hangzhou City, Zhejiang China
Email Us
contact@cytocan.com
Call Us
15267088941